News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cortice Biosciences Announces Enrollment Of A Phase 2 Trial Evaluating TPI 287 Plus Avastin® For Treatment Of Recurrent Glioblastoma Naive To Prior Anti-Angiogenic Therapy



1/9/2014 9:35:51 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Cortice Biosciences, Inc. announced today that enrollment has begun in the first stage of a Phase 2 open-label trial designed to evaluate the safety and efficacy of the Company's lead drug candidate, TPI 287, in combination with standard-of-care Avastin® (bevacizumab) for treatment of patients with recurrent glioblastoma (GBM) who have not received prior anti-angiogenic treatment for their disease (clinicaltrials.gov ID: NCT01933815). TPI 287 is an abeotaxane, a novel taxoid derivative that works similarly to taxane chemotherapeutics, such as Taxol®, Abraxane®, and Taxotere®, but with the distinct advantages of being able to circumvent common drug resistance mechanisms and cross the blood-brain barrier.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES